GuidelinesEAU Guidelines on Non–Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update
Introduction
The first European Association of Urology (EAU) guidelines on bladder cancer were published in 2002 [1]. Since then the guidelines have been continuously updated, and the most recent version is available from the EAU Web site, www.uroweb.org. An overview of the updated 2011 EAU guidelines on non–muscle-invasive bladder cancer (NMIBC) (Ta, T1, and carcinoma in situ [CIS]) is provided here.
Section snippets
Evidence acquisition
The panel members performed a systematic literature search for each section of the guidelines. Medline, Web of Science, and Embase databases were searched for original and review articles published between 2004 and 2010. Panel members selected records with the highest level of evidence according to a modified classification system from the Oxford Centre for Evidence-Based Medicine levels of evidence (LEs) [2]. Recommendations were graded to provide transparency regarding the underlying LE for
Epidemiology
Bladder cancer is the most common malignancy of the urinary tract. The worldwide age standardised rate (ASR) is 10.1 per 100 000 for men and 2.5 per 100 000 for women. In Europe, the highest incidence of bladder cancer (ASR) has been reported in the western region (23.6 in men and 5.4 in women) and in the southern region (27.1 in men and 4.1 in women), followed by northern Europe (16.9 in men and 4.9 in women). The lowest incidence has been observed in eastern European regions (14.7 in men and
Risk factors
Urologists should be aware of the various types of occupational exposures that may be related to urothelial carcinogens [5]. Aromatic amines were recognised first. At-risk groups include workers in the following industries: printing, iron and aluminium processing, industrial painting, and gas- and tar manufacturing (LE: 3). Another prominent risk factor is cigarette smoking, which triples the risk of developing bladder cancer and leads to higher mortality rates [6] (LE: 3).
Classification
The Tumour, Node, Metatasis (TNM) classification approved by the Union Internationale Contre le Cancer, which was updated in 2009, is used in these guidelines (Table 1) [7]. The new classification for grading NMIBCs proposed by the World Health Organisation (WHO) and the International Society of Urological Pathology was published by the WHO in 2004 (Table 2) [8]. New categories were defined among flat and papillary lesions. Among papillary lesions, they are papillary urothelial neoplasms of low
Diagnosis
Haematuria is the most common finding in NMIBC. Lower urinary tract symptoms may appear in patients with CIS.
Prognosis of TaT1 tumours
The classic way to categorise patients with TaT1 tumours is to divide them into risk groups based on prognostic factors derived from multivariate analyses. To predict separately the short- and long-term risks of both recurrence and progression in individual patients, a scoring system and risk tables were developed by the European Organisation for Research and Treatment of Cancer (EORTC) [33]. The EORTC database provided individual data for 2596 patients diagnosed with TaT1 tumours who did not
One immediate postoperative intravesical instillation
TaT1 tumours recur frequently and progress to muscle-invasive disease in a limited number of cases. It is therefore necessary to consider adjuvant therapy in all patients.
The results of a meta-analysis of seven randomised trials demonstrated that one immediate instillation of chemotherapy after TUR significantly reduced recurrence compared with TUR alone (LE: 1a) [37]. In absolute values, the reduction was 11.7%, which implies a 24.2% decrease in the corresponding relative risk. The efficacy of
Cystectomy for non–muscle-invasive bladder cancer
Immediate cystectomy can be considered for those patients who are at high risk of progression. According to the EORTC tables (Table 4, Table 5), these patients have multiple recurrent high-grade tumours, high-grade T1 tumours, and high-grade tumours with concurrent CIS. Cystectomy is advocated in patients with BCG failure. Delaying cystectomy in these patients may lead to decreased disease-specific survival [69].
Follow-up
Patients need to be followed up because of the risk of recurrence and progression; however, the frequency and duration of cystoscopies and upper urinary tract investigations should reflect the degree of risk [33]. When planning a follow-up schedule, the following aspects should be considered:
- •
Prompt detection of muscle-invasive and high-grade non–muscle-invasive recurrence is crucial because a delay in diagnosis and therapy can be life threatening.
- •
Tumour recurrence in the low-risk group is
References (72)
- et al.
Guidelines on bladder cancer
Eur Urol
(2002) - et al.
Prediction of progression of non–muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study
Eur Urol
(2008) - et al.
Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications
Eur Urol
(2010) - et al.
The role and impact of pathology review on stage and grade assessment on stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials
J Urol
(2000) - et al.
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder
Urology
(2005) - et al.
Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumors
J Urol
(2005) - et al.
Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups
J Urol
(2000) - et al.
Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers
Urology
(2005) - et al.
Differences between local and review urinary cytology and diagnosis of bladder cancer. An interobserver multicenter analysis
Eur Urol
(2002) - et al.
Cytology and urinary markers for the diagnosis of bladder cancer
Eur Urol Suppl
(2009)
Urine markers for bladder cancer surveillance: a systematic review
Eur Urol
Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis
Eur Urol
Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies
Eur Urol
Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder
Eur Urol
Photodynamic diagnosis in non–muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies
Eur Urol
Transurethral resection of non–muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study
Eur Urol
A second-look TUR in T1 transitional cell carcinoma: why?
Eur Urol
The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial
J Urol
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials
Eur Urol
Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guérin: the CUETO scoring model
J Urol
Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
J Urol
A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials
J Urol
Should all patients with non–muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study
Eur Urol
Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma
Eur Urol
Comparison of three schedules of intravesical epirubicin in patients with non–muscle-invasive bladder cancer
Eur Urol
One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe?
Eur Urol
A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Part on Superficial Bladder Cancer
J Urol
Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials
J Clin Epidemiol
The schedule and duration of intravesical chemotherapy in patients with non–muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials
Eur Urol
Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer—the 6th trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20 mg/40 ml, 30 mg/40 ml, 40 mg/40 ml
Eur Urol
Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials
Urology
Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity
J Urol
Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-α2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study
Eur Urol
Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up
Eur Urol
Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder
Eur Urol
An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non–muscle-invasive bladder cancer
Eur Urol
Cited by (675)
Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions
2024, Urologic Oncology: Seminars and Original InvestigationsValue of multiparametric magnetic resonance imaging for local staging of invasive urinary bladder tumours.
2023, Urologic Oncology: Seminars and Original InvestigationsBCG in Immunocompromised Patients: Is it effective? Is it safe?
2024, Bladder CancerFrom mucosal infection to successful cancer immunotherapy
2023, Nature Reviews Urology